Shikha Jain, MD, FACP

Suneel Kamath, MD

Arvind Dasari, MD, MS

Sakti Chakrabarti, MD

DocwireNews

A roundtable discussion, moderated by Shikha Jain, MD, FACP, discussed the treatment sequencing, management, and future directions of advanced colorectal cancer, as well as relevant clinical trial data from the 2024 American Society of Clinical Oncology Annual Meeting. Dr. Jain was joined by Suneel Kamath, MD; Arvind Dasari, MD, MS; and Sakti Chakrabarti, MD.
In the fifth segment of the roundtable series, the panel explores the impact of ctDNA in adjuvant settings, sequencing challenges for therapies like fruquintinib and TAS-102, and the transformative potential of KRAS-targeted therapies such as sotorasib.
View the next segment on <a href="https://www.docwirenews.com/post/future-directions-in-colorectal-cancer-care" target="_blank" rel="noopener">Future Directions in Colorectal Cancer Care</a>.
&#8212;
Dr. Dasari: As the PI for FRESCO-2, it is gratifying to hear about real-world experiences. Moving to other options, the SUNLIGHT trial demonstrated TAS-102 plus bevacizumab efficacy in the third-line setting, while fruquintinib approval spans third-line and beyond. A current debate is sequencing these therapies. How do you approach this?
Dr. Jain: That is exactly what I was going to ask next. Tell us about your sequencing strategies, which is challenging, especially for fellows entering practice, often influenced by their attending&#8217;s approach until new data emerges. What are your thoughts on this?
Dr. Kamath: It is indeed challenging without clear data. FRESCO-2 supports using fruquintinib before or after TAS-102 or regorafenib. I typically favor fruquintinib in the third line due to its bone marrow-sparing and proven efficacy, considering quality of life benefits. Trifluridine/tipiracil&#8217;s significant neutropenia makes spacing it after FOLFOX and FOLFIRI crucial, aiming for patients to complete multiple effective lines of therapy.
Dr. Chakrabarti: Logistics also play a role. Patients tired of carrying pumps prefer oral therapies like fruquintinib. Sequentially optimizing treatments ensures patients receive all effective options, maximizing survival.
Dr. Jain: Let us touch on CodeBreaK 300 and its impact.
Dr. Kamath: CodeBreaK 300 marks a milestone in KRAS targeting for colorectal cancer, highlighting the necessity of EGFR inhibition alongside KRAS targeting, unlike in other cancers. This chemotherapy-free regimen with sotorasib plus panitumumab shows a 30% response rate and impressive survival outcomes, setting a precedent for KRAS G12C in colorectal cancer.
Dr. Chakrabarti: Indeed, with emerging pan-RAS inhibitors, this paradigm is expanding.

Jordana Jampel

Potential Role of Monoclonal Antibodies in Asthma Structural Changes

Asthma

2024 Updated Stroke Guideline for Primary Care Clinicians

Stroke

Didier Debieuvre, MD

Cecilia Brown

Real-World French Prospective Study on Lung Cancer Highlights Progress in NSCLC Since 2000

WCLC 2024

Latest News

Sequencing Novel Therapies in Colorectal Cancer

Colorectal Cancer

The panel explores sequencing challenges for therapies like fruquintinib, TAS-102, and sotorasib for colorectal cancer.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe